{
    "symbol": "ATHX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-15 16:19:10",
    "content": " During the third quarter, we made good progress across several areas, including addressing our balance sheet and operating expenses, growing enrollment of patients in our masters to ischemic stroke trial, and pursuing discussions with potential business partners. We've subsequently received a notice of non-compliance from NASDAQ on October 14 that our market valuation of common stock had fallen below $35 million for 30 consecutive days and we have until April 12, 2023 to regain compliance and avoid the possibility of delisting."
}